Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36
Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs.
Naim Alkhouri and Mazen Noureddin join Louise and Roger to review highlights from Sunday at The Digital Liver Meeting. Naim, Mazen and Roger review results from drug trials that reveal that multiple drugs (monotherapies and combinations) with potent effects on liver fat reduction and fibrosis are moving through the pipeline. Louise discusses a trial that relies on non-invasive techniques to assess histologic improvement and fibrosis regression in cirrhotic patients, signaling one more way that non-invasive techniques might replace biopsy. Finally, Louise and Roger team up to discuss a US-based 20-year study showing us the many ways that lean NASH prognosis and co-morbidities differ from overweight or obese NASH. A session filled with information, theorizing and high spirits!